Compare Freeport-McMoRan Inc (FCX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs McKesson Corporation — how do they compare? Freeport-McMoRan Inc trades at $57.73 (market cap $87.65B), while McKesson Corporation trades at $842.99 (market cap $93.23B). The key difference: Freeport-McMoRan Inc and McKesson Corporation are close in size by market cap, and Freeport-McMoRan Inc pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| FCX | MCK | |
|---|---|---|
Market Cap | $87.65B | $93.23B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $995.69 |
52-Week Low | $35.34 | $659.01 |
Enterprise Value | $94.31B | $97.87B |
Dividend Yield | 0.98% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.
FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.
MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.
The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
